Amicus Therapeutics Inc [FOLD] stock prices are up 1.35% to $12.00 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The FOLD shares have gain 1.61% over the last week, with a monthly amount drifted -12.41%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 20, March 2024, Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report. In a post published today on Yahoo Finance, Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today issued its fourth annual Environmental, Social, and Governance (ESG) report. This year’s report highlights the strength of the Company’s corporate responsibility structure including increased efforts towards transparency in our environmental reporting, our deep commitment to ensuring broad and equitable access to our innovative therapies, fostering an inclusive culture to ensure equal representation and participation for all, and maintaining our leadership of strong business ethics and integrity.
From an analyst’s perspective:
Amicus Therapeutics Inc [NASDAQ: FOLD] stock has seen the most recent analyst activity on December 19, 2023, when Morgan Stanley upgraded its rating to a Overweight and also boosted its price target to $20 from $15. Previously, Morgan Stanley started tracking the stock with Equal-Weight rating on September 09, 2022, and set its price target to $14. SVB Leerink upgraded its rating to a Outperform and increased its price target to $16 on January 14, 2022. Stifel upgraded its rating to a Buy and raised its price target to $16 on November 15, 2021. JP Morgan upgraded its rating to Overweight for this stock on September 30, 2021, but kept the price target unchanged to $16.
The stock price of Amicus Therapeutics Inc [FOLD] has been fluctuating between $9.70 and $14.57 over the past year. Currently, Wall Street analysts expect the stock to reach $17 within the next 12 months. Amicus Therapeutics Inc [NASDAQ: FOLD] shares were valued at $12.00 at the most recent close of the market. An investor can expect a potential return of 41.67% based on the average FOLD price forecast.
Analyzing the FOLD fundamentals
The Amicus Therapeutics Inc [NASDAQ:FOLD] reported sales of 399.36M for trailing twelve months, representing a surge of 30.63%. Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at -0.19%, Pretax Profit Margin comes in at -0.38%, and Net Profit Margin reading is -0.38%. To continue investigating profitability, this company’s Return on Assets is posted at -0.19, Equity is -1.19 and Total Capital is -0.13. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 2.47.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 11.74 points at the first support level, and at 11.49 for the second support level. However, for the 1st resistance point, the stock is sitting at 12.13, and for the 2nd resistance point, it is at 12.27.
Amicus Therapeutics Inc [FOLD] reported earnings per share of -$0.11 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.06/share, meaning a difference of -$0.05 and a surprise factor of -83.30%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.07 per share as compared to estimates of -$0.08 per share, a difference of $0.01 representing a surprise of 12.50%.
Ratios To Look Out For
It’s worth pointing out that Amicus Therapeutics Inc [NASDAQ:FOLD]’s Current Ratio is 2.88. On the other hand, the Quick Ratio is 2.52, and the Cash Ratio is 1.47. Considering the valuation of this stock, the price to sales ratio is 8.88, the price to book ratio is 22.00.
Transactions by insiders
Recent insider trading involved MCGLYNN MARGARET G, Director, that happened on Mar 05 ’24 when 7500.0 shares were sold. Director, MCGLYNN MARGARET G completed a deal on Mar 04 ’24 to sell 7500.0 shares. Meanwhile, Executive Chairman Crowley John F sold 29181.0 shares on Mar 01 ’24.
